Rycarma
2 known investors
Rycarma develops a novel class of therapeutics called Rycals that target ryanodine receptors (RyRs) to correct calcium channel dysfunction in serious diseases with high unmet need. Its lead candidate, Surlorian, is aimed at addressing an underlying driver of heart failure progression by strengthening cardiac and skeletal muscle cells.
Investors · 2
Frequently asked questions
- What does Rycarma do?
- Rycarma develops a novel class of therapeutics called Rycals that target ryanodine receptors (RyRs) to correct calcium channel dysfunction in serious diseases with high unmet need. Its lead candidate, Surlorian, is aimed at addressing an underlying driver of heart failure progression by strengthening cardiac and skeletal muscle cells.
- Who are Rycarma's investors?
- Rycarma's investors include Kurma Partners, Pontifax Venture Capital.